State Street Corp Amends Syndax Pharma Stake Filing
Ticker: SNDX · Form: SC 13G/A · Filed: Jan 25, 2024 · CIK: 1395937
| Field | Detail |
|---|---|
| Company | Syndax Pharmaceuticals Inc (SNDX) |
| Form Type | SC 13G/A |
| Filed Date | Jan 25, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investment
TL;DR
**State Street just updated its Syndax Pharma holdings, confirming its continued stake.**
AI Summary
State Street Corporation, a major financial institution, filed an amended SC 13G/A on January 25, 2024, disclosing its ownership of Syndax Pharmaceuticals Inc. common stock as of December 31, 2023. This filing indicates State Street's continued passive investment in Syndax, a pharmaceutical company, under Rule 13d-1(b). This matters to investors as it shows a significant institutional holder maintains its position, potentially signaling confidence in Syndax's long-term prospects.
Why It Matters
This filing confirms State Street Corporation's ongoing institutional ownership in Syndax Pharmaceuticals, providing transparency on a major holder's position. It can influence investor sentiment and perception of the stock's stability.
Risk Assessment
Risk Level: low — This is a routine amendment by an institutional investor, indicating no immediate change in investment strategy or significant risk to the company.
Analyst Insight
A smart investor would note State Street's continued presence as a significant institutional holder, which can be a positive signal, but should conduct further due diligence on Syndax's fundamentals and pipeline rather than relying solely on this filing.
Key Players & Entities
- State Street Corporation (company) — the reporting person and institutional investor
- Syndax Pharmaceuticals Inc (company) — the subject company whose stock is being reported
- December 31, 2023 (date) — the date of the event requiring the filing
- January 25, 2024 (date) — the filing date of the SC 13G/A
Forward-Looking Statements
- State Street Corporation will maintain its passive investment in Syndax Pharmaceuticals Inc. for the foreseeable future. (State Street Corporation) — high confidence, target: 2025-01-25
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G filing, indicating a change or update to previously reported beneficial ownership of securities.
Who is the reporting person in this filing?
The reporting person is State Street Corporation, identified by CIK 0000093751 and IRS Number 04-2456637.
What is the subject company whose securities are being reported?
The subject company is Syndax Pharmaceuticals Inc, identified by CIK 0001395937.
What is the CUSIP number for the class of securities reported?
The CUSIP number for the common stock of Syndax Pharmaceuticals Inc is 87164F105.
What was the date of the event that required this filing?
The date of the event which required the filing of this statement was December 31, 2023.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 25, 2024 regarding Syndax Pharmaceuticals Inc (SNDX).